Antidiabetic Potential of a New Compound from Cassia fistula: Inhibiting α-Amylase

Summary

Researchers identified a new compound, hydroxy-phenyl-bi-benzopyran-hexol, extracted from Cassia fistula, which showed promise as an inhibitor of α-amylase, a key enzyme in carbohydrate digestion. This study combined traditional knowledge from Siddha medicine with computational and experimental methods, analyzing 915 bioactive compounds. The lead compound demonstrated a stable interaction with α-amylase, showing a binding energy of -69.70 ± 3.93 kJ/mol. The crude extract of the stem bark of Cassia fistula showed 57% inhibition of α-amylase, with an IC50 value of 237.25 μg/ml, lower than the 264.59 μg/ml value of the standard inhibitor acarbose. Although the results are promising, additional validation in animal studies is needed before advancing to clinical research.

Key points

The compound hydroxy-phenyl-bi-benzopyran-hexol demonstrated a binding energy of -69.70 ± 3.93 kJ/mol with α-amylase.
The Cassia fistula extract inhibited α-amylase by 57%, with an IC50 of 237.25 μg/ml.
The approach combined traditional Siddha knowledge with computational screening and in vitro validation.
The extract's IC50 was lower than that of the standard inhibitor acarbose (264.59 μg/ml).
The findings still need to be validated in animal studies before being considered for clinical use.

✦ For you

If you are looking for ways to control blood sugar, consider including Cassia fistula in your diet, whether as a tea or extract. Additionally, observe how your body reacts to different foods and your digestion after meals. Keeping a food diary can help identify patterns. If you have concerns about blood glucose, seek a qualified healthcare professional.

For practitionersExpand

Consider including Cassia fistula (Cassia fistula) in formulas for patients with hyperglycemia, especially those who have difficulty controlling carbohydrate digestion. Evaluate the interaction with other herbal medicines and the individual response of patients. The research suggests promising potential, but clinical validation is necessary before definitive recommendations.